New Data for DARZALEX (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple
December 11, 2017
December 11, 2017
ATLANTA, Georgia, Dec. 11 -- Johnson and Johnson issued the following news release:
Janssen Research & Development, LLC today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX(R) (daratumumab) had a manageable safety profile and a 12 percent rate of infusion reactions (IRs) in patients with relapsed or refractory multiple myeloma.1 These data were featured as an oral presentation today at the 59th American Soc . . .
Janssen Research & Development, LLC today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX(R) (daratumumab) had a manageable safety profile and a 12 percent rate of infusion reactions (IRs) in patients with relapsed or refractory multiple myeloma.1 These data were featured as an oral presentation today at the 59th American Soc . . .